Hainan Haiyao Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHE:000566
Hainan Haiyao Co Ltd is a China-based company engages in the research, development, manufacture, and sale of medicines and medical instrument. Its product includes cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The company distributes its products in domestic market and to overseas market. Digital China Information Service Co Ltd is a China-based company principally engaged in software and information technology (IT) service industry. Its services include technical services, agricultural informatization, application software development, special financial equipment, and integrated solutions for the financial, government, enterprises, telecommunications, agriculture, and other industries.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 758 out of 853
Universe
Global Universe 13410 out of 15120
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Avadel Pharmaceuticals Plc |
30
Medium
|
441 out of 853 |
| Tong Ren Tang Technologies Co., Ltd. |
32.5
High
|
540 out of 853 |
| Chong Kun Dang Pharmaceutical Corp. |
35.1
High
|
658 out of 853 |
| Mochida Pharmaceutical Co., Ltd. |
35.7
High
|
681 out of 853 |
| Hainan Haiyao Co., Ltd. |
37.4
High
|
758 out of 853 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.